Donepezil for psychotropic-induced memory loss

Journal of Clinical Psychiatry

Volumn 60, Issue 10, 1999, Pages 698-704

  Jacobsen, Frederick M ^a,b   Comas Díaz, Lillian ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b Transcultural Mental Health Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMANTADINE; AMFEBUTAMONE; BETHANECHOL; BUSPIRONE; CIMETIDINE; CISAPRIDE; CLOMIPRAMINE; CLONAZEPAM; CROMOGLYCATE DISODIUM; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; DOXAZOSIN; FLUOXETINE; GABAPENTIN; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE; LIOTHYRONINE SODIUM; METHYLPHENIDATE; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; OMEPRAZOLE; PAROXETINE; PHOSCHOL; PHOSPHATIDYLCHOLINE; PSYCHOTROPIC AGENT; SALBUTAMOL; SERTRALINE; TESTOSTERONE; TRANYLCYPROMINE; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM;

ADULT; AFFECTIVE NEUROSIS; AMNESIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; INSOMNIA; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYMPTOMATOLOGY; VOMITING;

EID: 0344995273     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n1009     Document Type: Article

References (37)

1. Janowski DS, Overstreet DH. The role of acetylcholine mechanisms in mood disorders. In: Bloom FE, Kupfer DF, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995: 945-956
2. Richelson E. Cholinergic transduction. In: Bloom FE, Kupfer DF, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:125-134
3. Arneric SP, Sullivan JP, Williams M. Neuronal nicotinic acetylcholine receptors. In: Bloom FE, Kupfer DF, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:95-110
4. Everett HC. The use of bethanechol chloride with tricyclic antidepressants. Am J Psychiatry 1975;132:1202-1204
5. Longo WE, Vernava AM III. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum 1993;36:696-708
6. Yamanishi Y, Ogura H, Kosasa T, et al. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: comparison with other inhibitors. In: Nagatsu T, Fisher A, Yoshida M, eds. Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases. New York, NY: Plenum Press; 1990:409-413
7. Aricept (donepezil hydrochloride) [package insert]. Teaneck, NJ: Eisai America Inc; Dec 1996
8. Bryson HM, Benfield P. Donepezil. Drugs Aging 1997;10:234-239
9. Rogers SL, Friedhoff LT, and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
11. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare, publication ADM 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
12. Ladd SL, Sommer SA, LaBerge S, et al. Effect of phosphatidylcholine on explicit memory. Clin Neuropharmacol 1993;16:540-549
13. Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol 1994;51:787-798
14. Small GW, La Rue A, Komo S, et al. Mnemonics usage and cognitive decline in age-associated memory impairment. Int Psychogeriatr 1997;91: 47-56
15. Schmand B, Jonker C, Geerlings MI, et al. Subjective memory complaints in the elderly: depressive symptoms and future dementia. Br J Psychiatry 1997;171:373-376
16. Caine ED, Weingartner H, Ludlow DL, et al. Qualitative analysis of scopolamine-mduced amnesia. Psychopharmacology (Berl) 1981;74:74-80
17. Callaway E, Halliday R, Naylor H, et al. Effects of oral scopolamine on human stimulus evaluation. Psychopharmacology (Berl) 1985;85: 133-138
18. Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res 1988;13:371-389
19. Jacobsen FM, Comas-Diaz L. Can reversal of non-geriatric psychotropic-induced memory loss by donepezil predict Alzheimer's disease [abstract]? Neurobiol Aging 1998;19(suppl 4S):abstr 177
20. Lendon CL, Ashall F, Goate AM. Exploring the etiology of Alzheimer's disease using molecular genetics. JAMA 1997;277:825-831
21. Post F. Dementia, depression, and pseudo-dementia. In: Benson DF, Blumer D, eds. Psychiatric Aspects of Neurological Disease. New York, NY: Grune & Stratton; 1975;99-120
22. Alexopoulos GS. Affective disorders. In: Sadavoy J, Lazarus ZLW, Jarvik LF, et al, eds. Comprehensive Review of Geriatric Psychiatry, II. Washington, DC: American Psychiatric Press; 1996:563-592
23. Speck CE, Kukull WA, Brenner DE, et al. History of depression as a risk factor for Alzheimer's disease. Epidemiology 1995;6:366-369
24. Devanand DP, Sano M, Tang MX, et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 1996;53:175-182
25. Braak H, Braak E. Alzheimer's disease starts in early adulthood [abstract]. Neurobiol Aging 1998;19(suppl 4S):abstr 318
26. Molchan SE, Martinez RA, Hill JL, et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev 1992;17:215-226
27. Ray PG, Meador KJ, Loring DW, et al. Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol 1992;5:72-77
28. Tariot PN, Patel SV, Cox C, et al. Age-related decline in central cholinergic function demonstrated with scopolamine. Psychopharmacology (Berl) 1996;125:50-56
29. Physicians' Desk Reference, 51st ed. Montvale, NJ: Medical Economics; 1998
30. Little JT, Broocks A, Martin A, et al. Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans. Psychopharmacology (Berl) 1995;120:280-288
31. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-1031
32. Gann H, Riemann D, Hohagen F, et al. The sleep structure of patients with anxiety disorders in comparison to that of healthy controls and depressive patients under baseline conditions and after cholinergic stimulation. J Affect Disord 1992;26:179-189
33. Riemann D, Hohagen F, Fritsch-Montero R, et al. Cholinergic and noradrenergic neurotransmission: impact on REM sleep regulation in healthy subjects and depressed patients. Acta Psychiatr Belg 1992;92:151-171
34. Sitaram N, Dube S, Keshavan M, et al. The association of supersensitive cholinergic REM-induction and affective illness within pedigrees. J Psychiatr Res 1987;21:487-497
35. Janowsky DS, Risch SC, Kennedy B, et al. Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release. Psychopharmacology (Berl) 1986;89:150-154
36. Dilsaver SC, Kronfol Z, Sackellares JC, et al. Antidepressant withdrawal syndromes: evidence supporting the cholinergic overdrive hypothesis. J Clin Psychopharmacol 1983;3:157-164
37. Hunter KD, Wilson WS. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 1995;40:983-989